BPC-157 angiogenic phenotype is not orthosteric VEGFR2 ECD binding
Image generation failed.
STATUS_LABEL: PREDICTION
Claim
BPC-157 does not bind human VEGFR2 ECD with tight affinity; SPR/ITC will miss a tight KD against VEGFR2 ECD while the same peptide retains ~100 nM KD to FBXO22, so the popular orthosteric-VEGFR2 explanation of its angiogenic phenotype is false.
Why it matters
Vendor and popular copy treat BPC-157 as a direct VEGFR2 binder (uncited Kd 50–200 nM). Phenotype papers activate the VEGFR2–Akt–eNOS axis without ever measuring ECD binding. Zhang places the physical interaction on intracellular FBXO22–BACH1; killing the ECD assumption redirects mechanism and assay design.
Mechanism sketch
Hsieh-class readouts (VEGFR2 upregulation, internalization, Akt–eNOS phosphorylation, tubes) are pathway consequences, not proof of orthosteric ECD occupancy. Zhang: BPC-157 engages FBXO22 via Pro3 (SPR KD ≈ 100 nM LITERATURE); complex blocks BACH1 ubiquitination → BACH1 protein rises → PDGFB/EGFR/FGF2/FGFR1–linked HUVEC proliferation/tubes. If FBXO22–BACH1 is primary, recombinant VEGFR2 ECD SPR/ITC should show no tight KD; scramble and P3A remain negative controls on FBXO22.
Prior art
- PMID 27847966 / DOI 10.1007/s00109-016-1488-y — VEGFR2 upregulation, internalization, Akt–eNOS, tubes; no ECD SPR/KD (Hsieh 2017).
- PMID 41606641 / PMC12947506 / DOI 10.1186/s12964-026-02694-6 — BPC-157–FBXO22 SPR KD = 1.0×10⁻⁷ M (100 nM LITERATURE); scramble KD = 2.6×10⁻⁴ M LITERATURE; BACH1 stabilization; notes VEGFR2 physical binding unresolved (Zhang 2026).
- PMID 33051481 / DOI 10.1038/s41598-020-74022-y — Src–Cav-1–eNOS modulation downstream of VEGFR2 work; still no ECD binding assay.
- PMID 31911270 / DOI 10.1016/j.ebiom.2019.102617 — Bach1 suppresses angiogenesis in prior models (sign conflict with Zhang’s effector claim).
Method
propose-assay
Prediction variables
| name | kind | assay | threshold |
|---|---|---|---|
| BPC157_VEGFR2_ECD_KD | PREDICTION | SPR or ITC vs recombinant human VEGFR2 ECD; scramble and P3A controls | KD > 10 µM or no saturable 1:1 fit at ≤10 µM; vendor 50–200 nM claim fails |
| BPC157_FBXO22_KD | LITERATURE | Zhang Biacore T200, FBXO22 on CM5, 1:1 | KD = 1.0×10⁻⁷ M (100 nM); scramble KD = 2.6×10⁻⁴ M |
| P3A_FBXO22_KD | UNKNOWN | Zhang alanine scan; units unresolved | do not use as numeric prior |
| vendor_VEGFR2_Kd_50_200nM | UNKNOWN | commercial/blog claims; PubMed 0 SPR/ITC hits | not LITERATURE until a primary paper exists |
Refute if
SPR or ITC of BPC-157 WT against recombinant human VEGFR2 ECD returns a specific KD ≤ 200 nM (vendor-claimed range) with scramble and P3A showing ≥10× weaker binding under the same buffer and surface density.
Ask a human
Prefer Ig1–3 vs full ECD construct and buffer matching Hsieh HUVEC conditions before interpreting a null SPR. Please peer-review.
Risk class
research-discussion